Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial

Tytuł :
Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial
Autorzy :
Hao Z
Huang X
Shao H
Tian F
Pokaż więcej
Temat :
dapagliflozin
serum uric acid
type 2 diabetes
Medicine (General)
R5-920
Źródło :
Therapeutics and Clinical Risk Management, Vol Volume 14, Pp 2407-2413 (2018)
Wydawca :
Dove Medical Press, 2018.
Rok publikacji :
2018
Kolekcja :
LCC:Medicine (General)
Typ dokumentu :
article
Opis pliku :
electronic resource
Język :
English
ISSN :
1178-203X
Relacje :
https://www.dovepress.com/effects-of-dapagliflozin-on-serum-uric-acid-levels-in-hospitalized-typ-peer-reviewed-article-TCRM; https://doaj.org/toc/1178-203X
Dostęp URL :
https://doaj.org/article/b83cc680032f47b697d9fc292dceb181
Prawa :
Journal Licence: CC BY-NC
Numer akcesji :
edsdoj.b83cc680032f47b697d9fc292dceb181
Czasopismo naukowe
Zhaohu Hao,1,* Xiao Huang,2,* Hailin Shao,1 Fengshi Tian1,3 1Department of Metabolic Disease Management Center, Tianjin 4th Central Hospital, Tianjin, China; 2NHC Key Laboratory of Hormones and Development (Tianjin Medical University), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University Metabolic Diseases Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China; 3Department of Cardiology, Tianjin 4th Central Hospital, The 4th Central Hospital Affiliated to Nankai University, The 4th Center Clinical College of Tianjin Medical University, Tianjin, China *These authors contributed equally to this work Background: Raised serum uric acid (SUA) level is commonly observed in patients with type 2 diabetes mellitus (T2DM) and is associated with increased morbidity and mortality. Sodium-glucose cotransporter 2 inhibitor, a novel oral diabetic drug, might exert a potential hypouricemic effect. We evaluated the effects of dapagliflozin on SUA levels in hospitalized T2DM patients with inadequate glycemic control. Methods: In this randomized controlled trial, 59 T2DM hospitalized patients with inadequate glycemic control were assigned to the dapagliflozin 10 mg group (n=29) or the control group (n=30). The primary outcome was changes in SUA levels from the baseline to good glycemic control. Additional outcomes included correlations between baseline SUA levels, urinary parameters, and the changes in SUA levels. This trial is registered in the Chinese Clinical Trial Registry (number ChiCTR1800015830). Results: Compared to baseline level, SUA levels had significantly decreased in both groups (P

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies